Results 171 to 180 of about 127,740 (362)
Roentgen examination of the afferent jejunal loop and duodenum after partial gastrectomy — Billroth II [PDF]
, 1958 S Kajas
openalex +1 more source
Perioperative use and accuracy of continuous glucose monitoring: A systematic review
Diabetes, Obesity and Metabolism, EarlyView.Abstract Perioperative impairment of glycaemic control significantly increases the risk of major postoperative complications. The use of continuous glucose monitoring (CGM) has demonstrated benefits in glycaemic control, but its use in the perioperative period remains unclear. The aim is to present the state of the art in the use and accuracy of CGM in
Léa Carlier +5 more
wiley +1 more source
Case of Partial Gastrectomy for Cancer of the Stomach. [PDF]
, 1923 R. P. Rowlands
openalex +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Effective weight management pharmacotherapies are a new alternative to bariatric surgery or health behaviour intervention (HBI) alone. Comparative cost‐effectiveness evaluations can guide decision‐making. We aimed to evaluate the cost‐effectiveness of sleeve gastrectomy (SG), Roux‐en‐Y gastric bypass (RYGB), semaglutide, tirzepatide, and ...
Nisha Gupta +5 more
wiley +1 more source
THE RESULTS OF TOTAL GASTRECTOMY FOR CANCER OF THE STOMACH
, 1952 John P. West, John R. Fenger
openalex +2 more sources
Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals
Diabetes, Obesity and Metabolism, EarlyView.Abstract Introduction Methylglyoxal (MGO) is a very reactive compound that modifies proteins, forming advanced glycation end products (AGEs) and activating inflammatory pathways. Elevated MGO levels have been linked to various diseases, including type 2 diabetes and atherosclerosis. However, the role of MGO and other glycating agents in the progression
Oluwatomisono I. Akinrimisi +12 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Metabolic‐bariatric surgery (MBS) remains a cornerstone of obesity treatment, yet 15%–30% of patients fail to achieve its intended benefits. Existing clinical and biochemical markers offer limited value in identifying who will respond favourably to this intervention.
Adrian Falkowski +6 more
wiley +1 more source